OTCMKTS:PZRXQ

PhaseRx Stock Forecast, Price & News

$0.03

+0.02 (+177.17 %)

(As of 04/12/2021 12:21 PM ET)

Add

Compare

Today's Range

$0.03

Now: $0.03▼

$0.03

50-Day Range

$0.01

MA: $0.03▼

$0.04

52-Week Range

$0.00

Now: $0.03▼

$0.08

Volume232 shs

Average Volume38,182 shs

Market Capitalization$298,095.00

P/E RatioN/A

Dividend YieldN/A

Beta-0.86

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:PZRXQ

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.phaserx.com

Phone206-805-6300

Employees10

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares11,690,000

Market Cap$298,095.00

Next Earnings DateN/A

OptionableNot Optionable

Headlines

No headlines for this company have been tracked by MarketBeat.com

MarketRank^™

Overall MarketRank^™

0.17 out of 5 stars

Medical Sector

1809th out of 2,016 stocks

Pharmaceutical Preparations Industry

724th out of 771 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for PhaseRx.

0.0 Community Rank

Outperform Votes
PhaseRx has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
PhaseRx has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about PhaseRx and other stocks. Vote “Outperform” if you believe PZRXQ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PZRXQ will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
PhaseRx does not currently pay a dividend.
Dividend Growth
PhaseRx does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PhaseRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
44.69% of the stock of PhaseRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$0.03

+0.02 (+177.17 %)

(As of 04/12/2021 12:21 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PZRXQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PZRXQ and its competitors with MarketBeat's FREE daily newsletter.

PhaseRx (OTCMKTS:PZRXQ) Frequently Asked Questions

What stocks does MarketBeat like better than PhaseRx?

Wall Street analysts have given PhaseRx a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PhaseRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PhaseRx?

PhaseRx saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 100 shares, a drop of 93.3% from the March 15th total of 1,500 shares. Based on an average daily volume of 15,000 shares, the days-to-cover ratio is currently 0.0 days.
View PhaseRx's Short Interest.

Who are PhaseRx's key executives?

PhaseRx's management team includes the following people:

Dr. Robert W. Overell, Co-Founder, CEO, Pres, Principal Accounting Officer, Sec. & Director (Age 65, Pay $487.17k)
Dr. Paul H. Johnson Ph.D., Co-Founder & Director (Age 78, Pay $33.12k)
Prof. Allan S. Hoffman, Co-Founder
Dr. Patrick S. Stayton Ph.D., Co-Founder
Dr. Oliver W. Press M.D., Ph.D., Co-Founder
Dr. Mary G. Prieve Ph.D., VP of Biology & Interim Head of Research
Mr. Spencer Lemons, Head of Bus. Devel.

Who are some of PhaseRx's key competitors?

Some companies that are related to PhaseRx include HST Global (HSTC), ProMetic Life Sciences (PFSCF), EPIRUS Biopharmaceuticals (EPRSQ), Woodbrook Group (WDBG), Rosetta Genomics (ROSGQ), MetaStat (MTST), Orexigen Therapeutics (OREXQ), AXM Pharma (AXMP), Alseres Pharmaceuticals (ALSE), Bohai Pharmaceuticals Group (BOPH), Immune Therapeutics (IMUN), Acusphere (ACUS), Affymax (AFFY), American Oriental Bioengineering (AOBI) and ARYx Therapeutics (ARYX).
View all of PZRXQ's competitors.

What is PhaseRx's stock symbol?

PhaseRx trades on the OTCMKTS under the ticker symbol "PZRXQ."

How do I buy shares of PhaseRx?

Shares of PZRXQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseRx's stock price today?

One share of PZRXQ stock can currently be purchased for approximately $0.03.

How much money does PhaseRx make?

PhaseRx has a market capitalization of $298,095.00.

How many employees does PhaseRx have?

PhaseRx employs 10 workers across the globe.

What is PhaseRx's official website?

The official website for PhaseRx is www.phaserx.com.

Where are PhaseRx's headquarters?

PhaseRx is headquartered at 410 W. Harrison Street Suite 300, Seattle WA, 98119.

How can I contact PhaseRx?

PhaseRx's mailing address is 410 W. Harrison Street Suite 300, Seattle WA, 98119. The company can be reached via phone at 206-805-6300 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

PhaseRx Stock Forecast, Price & News

Adding

Adding

Adding PhaseRx, Inc.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

0.0 Community Rank

Outperform Votes

Underperform Votes